Table 2.
Summary of Tumor Shrinkage and Mean Tumor-Absorbed Dose from Tracer and Therapy Imaging
| |
Patient 1 |
Patient 2 |
Patient 3 |
Patient 4 |
||
|---|---|---|---|---|---|---|
| Large pelvic tumor | Small pelvic tumor | Iliac tumor | Inguinal tumor | Pelvic tumor | Abdominal tumor | |
| Initial tumor volume | 313 mL | 39 mL | 234 mL | 140 mL | 400 mL | 408 mL |
| Shrinkage (during tracer imaging) | 1% | −10% | 23% | 18% | 4% | −2% |
| Shrinkage (during therapy imaging) | 26% | 31% | 17% | 31% | 3% | 17% |
| Total shrinkage | 31% | 27% | 45% | 49% | 5% | 15% |
| Residence time (using tracer imaging) | 2.70 hours | 0.41 hours | 0.71 hours | 0.44 hours | 1.11 hours | 1.89 hours |
| Residence time (using therapy imaging) | 2.16 hours | 0.25 hours | 0.59 hours | 0.37 hours | 0.85 hours | 1.55 hours |
| Predicted dose (using tracer imaging) | 359 cGy | 360 cGy | 192 cGy | 181 cGy | 183 cGy | 281 cGy |
| Delivered dose (using therapy imaging) | 334 cGy (7%)a | 283 cGy (21%) | 211 cGy (−10%) | 207 cGy (−14%) | 146 cGy (20%) | 241 cGy (14%) |
| Delivered dose (assuming static tumor volume) | 278 cGy (−20%)b | 243 cGy (−17%) | 147 cGy (−43%) | 141 cGy (−47%) | 148 cGy (1%) | 239 cGy (−1%) |
a
Difference between tracer-predicted and therapy-delivered doses.
b
Difference between therapy dose estimated by assuming a static tumor volume from the initial computed tomography scan and the result in the row above, where the tumor regression measured over multiple scans was included in the calculation.